Home›Terbinafine›Terbinafine + Flecainide

Does Terbinafine Interact with Flecainide?

The terbinafine tablet label names flecainide among drugs metabolized by CYP2D6. It advises careful monitoring with coadministration because terbinafine inhibits this enzyme.

Label evidence and limitations

Named-drug label evidence. The label discusses possible clinician-directed dose reduction of the CYP2D6 substrate. This comparison does not validate an individualized dose or CDI severity category.

Product scope: Oral terbinafine tablets, not topical antifungal creams.

Read the DailyMed label: These highlights do not include all the information needed to use TERBINAFINE TABLETS safely and effectively. See full prescribing information for TERBINAFINE TABLETS. TERBINAFINE tablets, for oral use Initial U.S. Approval: 1992
Section: 7.1 Drug-Drug Interactions. Compared version 5, label date 2026-09-10. The linked label may be updated after this comparison.

This comparison uses the label identifier saved with the CDI record. The compared version may be newer than the original extraction.

AI-assisted source comparison dated 2026-10-16. This is a comparison of label text, not independent clinical review or an individual safety assessment. CDI's stored severity category is not an FDA-assigned rating. Confirm your exact medicines and formulations with your pharmacist or prescriber before changing treatment.

Stored CDI classification: Moderate
Management: Confirm exact products with your pharmacist
Data Source: Product label via NLM DailyMed

What To Tell Your Doctor or Pharmacist

If you are taking Terbinafine and your doctor is considering prescribing Flecainide (or vice versa), make sure to:

Inform your doctor and pharmacist of all current medications, including over-the-counter drugs and supplements
Ask whether the benefits of combining these medications outweigh the risks for your specific situation
Ask what symptoms to watch for that would indicate the interaction is causing problems
Never stop or change either medication without first consulting your healthcare provider

💊 Terbinafine(Silka Cream)+💊 Flecainide

Severity & Interaction Details

🟡

Stored CDI classification: moderate

Named-drug label evidence

The label discusses possible clinician-directed dose reduction of the CYP2D6 substrate. This comparison does not validate an individualized dose or CDI severity category.

Stored CDI scale

MinorContra

On record

Yes

Drug A class

—

Drug B class

—

Source

NLP:terbinafine

How to interpret this source comparison

The label discusses possible clinician-directed dose reduction of the CYP2D6 substrate. This comparison does not validate an individualized dose or CDI severity category.

About Terbinafine and Flecainide

Terbinafine is also sold under the brand name Lamisil.

Source and Limitations

This record was produced by automated extraction from drug-label information, including AI processing. The summary and mechanism are not verbatim FDA quotations. The drug profiles below may describe different formulations from the source label. Confirm the exact product and route with your pharmacist. This page does not establish independent clinical review.

📖 Source: NLP:terbinafine

Share this result:

WhatsApp Text / SMS Email

Also share on:X Facebook

Add more drugs

Check Terbinafine and Flecainide against your full medication list

Most patients take more than two medications. CDI checks every pair across up to 20 drugs simultaneously — including OTCs and common supplements.

Add more drugs →

How this information is prepared: CDI uses automated extraction, including AI, to summarize drug labeling from openFDA and includes separately identified curated-reference records. RxNorm helps identify medications; it does not verify interaction claims. Extracted summaries and CDI severity classifications can contain errors and are not verbatim FDA statements or independent clinical review. Maintained by CheckDrugInteractions.com. See our methodology or report a correction at support@checkdruginteractions.com.

Data sourced from U.S. FDA drug labeling via openFDA and the NIH National Library of Medicine, supplemented with a small number of well-established interactions from curated clinical references. For informational purposes only. Always consult your pharmacist or physician.